AbbVie (ABBV) Stock Forecast, Price Target & Predictions
ABBV Stock Forecast
AbbVie stock forecast is as follows: an average price target of $167.54 (represents a -13.73% downside from ABBV’s last price of $194.21) and a rating consensus of 'Buy', based on 29 wall street analysts offering a 1-year stock forecast.
ABBV Price Target
The average price target for AbbVie (ABBV) is $167.54 based on 1-year price targets from 29 Wall Street analysts in the past 3 months, with a price target range of $214.00 to $127.00. This represents a potential -13.73% downside from ABBV's last price of $194.21.
ABBV Analyst Ratings
According to 29 Wall Street analysts, AbbVie's rating consensus is 'Buy'. The analyst rating breakdown for ABBV stock is 0 'Strong Buy' (0.00%), 21 'Buy' (72.41%), 8 'Hold' (27.59%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
AbbVie Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 23, 2024 | Christopher Raymond | Raymond James | $209.00 | $197.35 | 5.90% | 7.62% |
| Jul 19, 2024 | Evan Seigerman | BMO Capital | $214.00 | $172.01 | 24.41% | 10.19% |
| Jun 18, 2024 | Christopher Raymond | Raymond James | $190.00 | $171.36 | 10.88% | -2.17% |
| Jun 05, 2024 | Rajesh Kumar | HSBC | $185.00 | $162.14 | 14.10% | -4.74% |
| May 24, 2024 | James Shin | Deutsche Bank | $175.00 | $156.96 | 11.49% | -9.89% |
| May 17, 2024 | Louise Chen | Cantor Fitzgerald | $200.00 | $164.35 | 21.69% | 2.98% |
| Apr 29, 2024 | Evan Seigerman | BMO Capital | $180.00 | $158.58 | 13.50% | -7.32% |
| Mar 27, 2024 | Carter Gould | Barclays | $195.00 | $179.79 | 8.46% | 0.41% |
| Jan 29, 2024 | Tim Lugo | William Blair | $190.00 | $163.91 | 15.92% | -2.17% |
| Nov 09, 2023 | Christopher Raymond | Raymond James | $170.00 | $142.03 | 19.69% | -12.47% |
The latest AbbVie stock forecast, released on Aug 23, 2024 by Christopher Raymond from Raymond James, set a price target of $209.00, which represents a 5.90% increase from the stock price at the time of the forecast ($197.35), and a 7.62% increase from ABBV last price ($194.21).
AbbVie Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 11 |
| Avg Price Target | $209.00 | $204.33 | $189.55 |
| Last Closing Price | $194.21 | $194.21 | $194.21 |
| Upside/Downside | 7.62% | 5.21% | -2.40% |
In the current month, the average price target of AbbVie stock is $209.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 7.62% increase as opposed to AbbVie's last price of $194.21. This month's average price target is up 2.29% compared to last quarter, and up 10.26% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 23, 2024 | Wells Fargo | Buy | Buy | Hold |
| Aug 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 12, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jul 26, 2024 | Barclays | Overweight | Overweight | Hold |
| Jul 19, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jul 11, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jul 02, 2024 | Sandler O'Neil | Underperform | Underperform | Hold |
| Jul 02, 2024 | Sandler O'Neill | Buy | Buy | Hold |
| Jun 18, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 05, 2024 | HSBC | - | Buy | Upgrade |
AbbVie's last stock rating was published by Wells Fargo on Aug 23, 2024. The company gave ABBV a "Buy" rating, the same as its previous rate.
AbbVie Financial Forecast
AbbVie Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $13.93B | $13.87B | $12.22B | $15.12B | $14.81B | - | $13.54B | $14.89B | $14.34B | $13.96B | $13.01B | $13.86B | $12.90B | $10.43B | $8.62B | $8.70B | $8.48B | $8.26B | $7.83B | $8.30B | $8.24B |
| Avg Forecast | $15.75B | $15.02B | $14.55B | $13.03B | $14.65B | $14.27B | $14.02B | $11.93B | $14.03B | $13.72B | $13.54B | $12.17B | $15.33B | $14.96B | $14.66B | $13.61B | $14.95B | $14.30B | $13.63B | $12.77B | $13.70B | $12.72B | $9.94B | $8.33B | $8.69B | $8.38B | $8.10B | $7.77B | $8.48B | $7.77B |
| High Forecast | $16.11B | $15.37B | $14.88B | $13.33B | $14.99B | $14.52B | $14.34B | $12.20B | $14.34B | $13.83B | $13.85B | $12.44B | $15.68B | $15.30B | $14.66B | $14.00B | $15.38B | $14.71B | $14.02B | $13.13B | $14.09B | $13.08B | $10.22B | $8.56B | $8.94B | $8.62B | $8.33B | $8.00B | $10.18B | $9.33B |
| Low Forecast | $15.63B | $14.92B | $14.45B | $12.94B | $14.55B | $14.18B | $13.92B | $11.84B | $13.94B | $13.65B | $13.44B | $12.08B | $15.22B | $14.85B | $14.66B | $13.21B | $14.51B | $13.88B | $13.23B | $12.39B | $13.30B | $12.35B | $9.65B | $8.08B | $8.44B | $8.13B | $7.86B | $7.55B | $6.78B | $6.22B |
| # Analysts | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 6 | 6 | 7 | 7 | 7 | 10 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 13 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.02% | 1.02% | 1.00% | 0.99% | 0.99% | - | 0.99% | 1.00% | 1.00% | 1.02% | 1.02% | 1.01% | 1.01% | 1.05% | 1.04% | 1.00% | 1.01% | 1.02% | 1.01% | 0.98% | 1.06% |
AbbVie's average Quarter revenue forecast for Dec 23 based on 9 analysts is $14.03B, with a low forecast of $13.94B, and a high forecast of $14.34B. ABBV's average Quarter revenue forecast represents a 0.70% increase compared to the company's last Quarter revenue of $13.93B (Sep 23).
AbbVie EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 6 | 6 | 7 | 7 | 7 | 10 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 13 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | $2.44B | $5.11B | $3.10B | $6.03B | $4.97B | - | $5.03B | $6.83B | $6.41B | $3.98B | $6.71B | $1.19B | $5.42B | $1.50B | $4.22B | $4.14B | $2.98B | $1.67B | $3.43B | $-1.55B | $3.54B |
| Avg Forecast | $5.76B | $5.49B | $5.32B | $4.76B | $5.36B | $5.22B | $5.13B | $9.05B | $5.13B | $5.02B | $4.95B | $8.23B | $5.61B | $6.81B | $5.36B | $7.48B | $6.79B | $6.19B | $3.98B | $6.43B | $1.16B | $5.30B | $1.39B | $3.90B | $4.10B | $2.95B | $1.63B | $3.28B | $-1.58B | $3.33B |
| High Forecast | $5.89B | $5.62B | $5.44B | $4.87B | $5.48B | $5.31B | $5.24B | $10.86B | $5.24B | $5.06B | $5.06B | $9.87B | $5.73B | $8.17B | $5.36B | $8.97B | $8.14B | $7.43B | $4.77B | $7.71B | $1.39B | $6.36B | $1.67B | $4.68B | $4.93B | $3.53B | $1.96B | $3.94B | $-1.27B | $3.99B |
| Low Forecast | $5.72B | $5.45B | $5.28B | $4.73B | $5.32B | $5.18B | $5.09B | $7.24B | $5.09B | $4.99B | $4.91B | $6.58B | $5.57B | $5.45B | $5.36B | $5.98B | $5.43B | $4.95B | $3.18B | $5.14B | $924.72M | $4.24B | $1.11B | $3.12B | $3.28B | $2.36B | $1.30B | $2.63B | $-1.90B | $2.66B |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.49% | 1.03% | 0.38% | 1.08% | 0.73% | - | 0.67% | 1.01% | 1.04% | 1.00% | 1.04% | 1.03% | 1.02% | 1.07% | 1.08% | 1.01% | 1.01% | 1.02% | 1.05% | 0.98% | 1.06% |
9 analysts predict ABBV's average Quarter EBITDA for Dec 23 to be $5.13B, with a high of $5.24B and a low of $5.09B. This is 109.97% upper than AbbVie's previous annual EBITDA (Sep 23) of $2.44B.
AbbVie Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 6 | 6 | 7 | 7 | 7 | 10 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 13 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | $1.78B | $2.02B | $239.00M | $2.47B | $3.95B | - | $4.49B | $4.04B | $3.18B | $766.00M | $3.55B | $36.00M | $2.31B | $-738.00M | $3.01B | $2.80B | $1.88B | $741.00M | $2.46B | $-1.83B | $2.75B |
| Avg Forecast | $5.90B | $5.62B | $5.59B | $4.60B | $5.24B | $5.22B | $4.54B | $5.40B | $4.95B | $5.08B | $5.02B | $4.91B | $6.31B | $3.38B | $5.89B | $4.46B | $4.02B | $3.07B | $766.00M | $3.40B | $35.12M | $2.26B | $-687.45M | $2.78B | $2.78B | $1.86B | $724.24M | $2.35B | $-1.86B | $2.58B |
| High Forecast | $6.07B | $5.79B | $5.75B | $4.73B | $5.39B | $5.31B | $4.68B | $6.48B | $4.98B | $5.19B | $5.16B | $5.89B | $6.49B | $4.05B | $5.89B | $5.35B | $4.82B | $3.68B | $919.20M | $4.08B | $42.14M | $2.71B | $-549.96M | $3.34B | $3.33B | $2.23B | $869.08M | $2.82B | $-1.49B | $3.10B |
| Low Forecast | $5.84B | $5.57B | $5.54B | $4.55B | $5.19B | $5.17B | $4.50B | $4.32B | $4.89B | $4.97B | $4.97B | $3.93B | $6.25B | $2.70B | $5.89B | $3.57B | $3.22B | $2.46B | $612.80M | $2.72B | $28.09M | $1.81B | $-824.94M | $2.23B | $2.22B | $1.49B | $579.39M | $1.88B | $-2.24B | $2.07B |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.35% | 0.40% | 0.05% | 0.39% | 1.17% | - | 1.01% | 1.01% | 1.04% | 1.00% | 1.04% | 1.03% | 1.02% | 1.07% | 1.08% | 1.01% | 1.01% | 1.02% | 1.05% | 0.98% | 1.06% |
AbbVie's average Quarter net income forecast for Dec 23 is $4.95B, with a range of $4.89B to $4.98B. ABBV's average Quarter net income forecast represents a 178.20% increase compared to the company's last Quarter net income of $1.78B (Sep 23).
AbbVie SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 6 | 6 | 7 | 7 | 7 | 10 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 13 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | $3.37B | $3.27B | $3.04B | $3.42B | $3.30B | - | $3.13B | $3.26B | $3.08B | $3.16B | $2.84B | $3.23B | $2.85B | $3.53B | $1.70B | $1.95B | $1.66B | $1.65B | $1.68B | $1.93B | $1.92B |
| Avg Forecast | $3.72B | $3.55B | $3.43B | $3.08B | $3.46B | $3.37B | $3.31B | $3.76B | $3.31B | $3.24B | $3.20B | $3.42B | $3.62B | $3.28B | $3.46B | $3.11B | $3.24B | $2.98B | $3.16B | $2.72B | $3.15B | $2.78B | $3.29B | $1.57B | $1.93B | $1.64B | $1.62B | $1.61B | $1.97B | $1.80B |
| High Forecast | $3.80B | $3.63B | $3.51B | $3.15B | $3.54B | $3.43B | $3.38B | $4.51B | $3.39B | $3.26B | $3.27B | $4.10B | $3.70B | $3.93B | $3.46B | $3.73B | $3.89B | $3.57B | $3.80B | $3.27B | $3.78B | $3.34B | $3.94B | $1.88B | $2.32B | $1.96B | $1.94B | $1.93B | $2.36B | $2.17B |
| Low Forecast | $3.69B | $3.52B | $3.41B | $3.05B | $3.43B | $3.35B | $3.29B | $3.01B | $3.29B | $3.22B | $3.17B | $2.73B | $3.59B | $2.62B | $3.46B | $2.49B | $2.59B | $2.38B | $2.53B | $2.18B | $2.52B | $2.23B | $2.63B | $1.25B | $1.55B | $1.31B | $1.29B | $1.28B | $1.58B | $1.44B |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.04% | 1.02% | 0.89% | 0.94% | 1.01% | - | 1.01% | 1.01% | 1.04% | 1.00% | 1.04% | 1.03% | 1.02% | 1.07% | 1.08% | 1.01% | 1.01% | 1.02% | 1.05% | 0.98% | 1.06% |
AbbVie's average Quarter SG&A projection for Dec 23 is $3.31B, based on 9 Wall Street analysts, with a range of $3.29B to $3.39B. The forecast indicates a -1.84% fall compared to ABBV last annual SG&A of $3.37B (Sep 23).
AbbVie EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 6 | 6 | 7 | 7 | 7 | 10 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 13 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | $1.01 | $1.14 | $0.14 | $1.40 | $2.22 | - | $2.52 | $2.29 | $1.80 | $0.43 | $2.01 | $0.02 | $1.31 | $-0.42 | $2.04 | $1.89 | $1.27 | $0.50 | $1.66 | $-1.23 | $1.83 |
| Avg Forecast | $3.33 | $3.17 | $3.15 | $2.60 | $2.96 | $2.95 | $2.57 | $2.25 | $2.79 | $2.87 | $2.83 | $2.51 | $3.56 | $3.57 | $3.32 | $3.14 | $3.28 | $3.21 | $3.08 | $2.81 | $2.85 | $2.76 | $2.20 | $2.25 | $2.19 | $2.30 | $2.21 | $2.06 | $1.98 | $1.90 |
| High Forecast | $3.43 | $3.27 | $3.25 | $2.67 | $3.04 | $3.00 | $2.64 | $2.32 | $2.81 | $2.93 | $2.92 | $2.58 | $3.67 | $3.68 | $3.32 | $3.26 | $3.41 | $3.33 | $3.20 | $2.91 | $2.96 | $2.86 | $2.28 | $2.33 | $2.27 | $2.38 | $2.29 | $2.14 | $2.38 | $2.28 |
| Low Forecast | $3.30 | $3.14 | $3.13 | $2.57 | $2.93 | $2.92 | $2.54 | $2.23 | $2.76 | $2.80 | $2.81 | $2.49 | $3.53 | $3.54 | $3.32 | $3.02 | $3.16 | $3.09 | $2.96 | $2.70 | $2.74 | $2.65 | $2.11 | $2.16 | $2.11 | $2.21 | $2.13 | $1.98 | $1.58 | $1.52 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.35% | 0.40% | 0.06% | 0.39% | 0.62% | - | 0.80% | 0.70% | 0.56% | 0.14% | 0.72% | 0.01% | 0.47% | -0.19% | 0.91% | 0.86% | 0.55% | 0.23% | 0.81% | -0.62% | 0.96% |
According to 9 Wall Street analysts, AbbVie's projected average Quarter EPS for Dec 23 is $2.79, with a low estimate of $2.76 and a high estimate of $2.81. This represents a 176.53% increase compared to ABBV previous annual EPS of $1.01 (Sep 23).
AbbVie Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PFE | Pfizer | $29.27 | $46.29 | 58.15% | Hold |
| BMY | Bristol-Myers Squibb Company | $49.13 | $65.43 | 33.18% | Hold |
| MRK | Merck | $115.86 | $127.74 | 10.25% | Buy |
| JNJ | Johnson & Johnson | $165.52 | $176.29 | 6.51% | Buy |
| GILD | Gilead Sciences | $82.81 | $80.00 | -3.39% | Buy |
| AMGN | Amgen | $332.45 | $286.95 | -13.69% | Buy |
| ABBV | AbbVie | $194.21 | $167.54 | -13.73% | Buy |
| LLY | Eli Lilly and Company | $923.71 | $753.65 | -18.41% | Buy |
ABBV Forecast FAQ
Is AbbVie a good buy?
Yes, according to 29 Wall Street analysts, AbbVie (ABBV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 21 'Buy' recommendations, accounting for 72.41% of ABBV's total ratings.
What is ABBV's price target?
AbbVie (ABBV) average price target is $167.54 with a range of $127 to $214, implying a -13.73% from its last price of $194.21. The data is based on 29 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will AbbVie stock go up soon?
According to Wall Street analysts' prediction for ABBV stock, the company can go down by -13.73% (from the last price of $194.21 to the average price target of $167.54), up by 10.19% based on the highest stock price target, and down by -34.61% based on the lowest stock price target.
Can AbbVie stock reach $300?
ABBV's average twelve months analyst stock price target of $167.54 does not support the claim that AbbVie can reach $300 in the near future.
What is AbbVie's current price target trend?
1 Wall Street analyst forecast a $209 price target for AbbVie (ABBV) this month, up 7.62% from its last price of $194.21. Compared to the last 3 and 12 months, the average price target increased by 5.21% and decreased by -2.40%, respectively.
What are AbbVie's analysts' financial forecasts?
AbbVie's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $54.87B (high $56.05B, low $54.49B), average EBITDA is $24.75B (high $26.89B, low $22.83B), average net income is $20.4B (high $21.86B, low $19.18B), average SG&A $13.89B (high $14.86B, low $13.07B), and average EPS is $10.72 (high $11.01, low $10.62). ABBV's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $58.35B (high $59.68B, low $57.94B), average EBITDA is $21.33B (high $21.82B, low $21.18B), average net income is $21.7B (high $22.34B, low $21.5B), average SG&A $13.77B (high $14.08B, low $13.67B), and average EPS is $12.25 (high $12.62, low $12.14).
Did the ABBV's actual financial results beat the analysts' financial forecasts?
Based on AbbVie's last annual report (Dec 2022), the company's revenue was $58.05B, which missed the average analysts forecast of $58.57B by -0.88%. Apple's EBITDA was $19.66B, missing the average prediction of $25.26B by -22.16%. The company's net income was $11.84B, missing the average estimation of $20.03B by -40.92%. Apple's SG&A was $15.26B, beating the average forecast of $13.46B by 13.36%. Lastly, the company's EPS was $6.65, missing the average prediction of $13.6 by -51.09%. In terms of the last quarterly report (Sep 2023), AbbVie's revenue was $13.93B, beating the average analysts' forecast of $13.72B by 1.52%. The company's EBITDA was $2.44B, missing the average prediction of $5.02B by -51.31%. AbbVie's net income was $1.78B, missing the average estimation of $5.08B by -64.99%. The company's SG&A was $3.37B, beating the average forecast of $3.24B by 4.16%. Lastly, the company's EPS was $1.01, missing the average prediction of $2.87 by -64.78%